Case 23 Vertex Pharmaceuticals

B. Rajesh Kumar
Additional contact information
B. Rajesh Kumar: Institute of Management Technology

A chapter in Rising Stars, 2024, pp 177-183 from Springer

Abstract: Abstract Vertex Pharmaceuticals is a global biotechnology company which focuses on specialty markets to create innovative medicines for treating serious diseases like cystic fibrosis. Vertex have a pipeline of investigational therapies to find cure for diseases like sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The four medicines TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO are used to treat over 83,000 people for cystic fibrosis in regions of North America, Europe, and Australia. As of December 31, 2021, the company had approximately 3900 employees. The common stock of Vertex is traded on Nasdaq Global Select Market under the symbol “VRTX.” The company has headquarters in Boston and London. Vertex focuses on investment in R&D to discover and develop innovative medicines by combining transformative advances in the field of human diseases and the science of therapeutics. Vertex focuses on strategic alliances and M&A as a part of its growth strategy. An investment of $100 in the Vertex Pharma stock on July 24,1991 would have led to the invested amount accumulated to $7141.56 by December 3, 2022, reflecting a return of 7041.56%. The total cumulative monthly return for Vertex stock was 82.6% during the period 2018–2022.

Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:mgmchp:978-3-031-50032-9_23

Ordering information: This item can be ordered from
http://www.springer.com/9783031500329

DOI: 10.1007/978-3-031-50032-9_23

Access Statistics for this chapter

More chapters in Management for Professionals from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().